At the same time as the UCL study was released, another study of a new drug, retatrutide, found that it could be even more effective with participants losing 24% of their body weight over 48 weeks, partly because it has an impact on metabolism as well as appetite
Over the next decade, several longer-acting versions were developed, including: Victoza (liraglutide) approved in 2010 Bydureon approved in 2012 Trulicity approved in 2014 During this period the medications were primarily prescribed for diabetes , and awareness outside medical circles was relatively limited
Other notable benefits of using Ipamorelin include: Improved athletic performance Decreased signs of aging Prevention of the onset of certain diseases Balanced hormone levels in women Why Use the Sermorelin Ipamorelin Combination
This consistency is especially useful when examining dose-response relationships
In the STEP 1 extension trial, most people regained a significant amount of weight within a year, though not everyone, and not the same amount